The Advantages Of VentriPoint’s VMS™ System Over MRI To Be Presented At EUROECHO

VentriPoint Diagnostics Ltd.VPT - TSX Venture
Shares issued: - 102.6 million
Fully diluted: - 134.0 million

*****************************

VentriPoint announced today that Dr. Shelby Kutty is presenting his clinical paper on VMS™ at The Annual Congress of the European Association of Echocardiography, EUROECHO, December 7 -10^th, 2011.

Dr. Kutty was the topic of an early December VentriPoint news release, as he is leading a specialty trial in Omaha comparing MRI to VMS. Of significance, the trial was not paid for by VentriPoint and was initiated by Dr. Kutty.

The paper is definitive and as stated in the press release ìnnovative as it clearly outlines the advantage of using the VMS™ in therapeutic follow through for clinical studies with systemic single ventricle vs. MRI.

To be hosted in Budapest, Hungary, EUROECHO is considered to be one of the largest and most important scientific meetings on non-invasive cardiovascular diagnosis in the world. The Congress has over 70,000 members and is very well attended by its member practitioners.

In addition VentriPoint has announced Victor Ton its European Sales Manager, will be representing the company at its booth at the Congress.

Victor Ton has a 17 year plus career in imaging/diagnostics sales and will be based in the Netherlands.

VentriPoint continues to expand its product line and now has an increased presence in Europe where its product is approved for sale. We expect a continuation of good news.

Click here to view today’s news release.